SAMDI Tech, a provider of label-free drug discovery solutions, has partnered with Enamine, a supplier of drug-like screening compounds, to expand the number of molecules in their small molecule compound libraries. Through the partnership, SAMDI Tech will be able to offer its clients access to more than a half-million screening compounds.

“This partnership will provide us with the tools we need to continue to deliver increasingly comprehensive solutions to our clients,” said SAMDI Tech CEO Emilio Córdova. “With Enamine’s support, not only is it possible for researchers to screen for new leads against their novel targets, but our technology will allow them to narrow them down faster.”

Using its label-free and high-throughput SAMDI assay, the team at SAMDI Tech can screen a client’s target against any number of compounds. As hits are found, Enamine provides support with the follow-up chemistry needed to validate and optimize the compound’s activity.

“We are proud to expand the reach of our compound collection through SAMDI Tech,” said Irina Yavnyuk, director of business development for Enamine.